- Home
- PCVX vs LEGN Comparison
PCVX vs LEGN Comparison
Compare PCVX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PCVX | LEGN |
|---|---|---|
| Price | $57.73 | $20.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $98.33 | $63.08 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 05-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $46.27 |
| Revenue Next Year | N/A | $28.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $16.24 |
| 52 Week High | $76.61 | $45.30 |
Technical Indicators
Market Signals| Indicator | PCVX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 60.43 |
| Support Level | $42.30 | $16.24 |
| Resistance Level | $65.00 | $21.58 |
| Average True Range (ATR) | 3.01 | 0.91 |
| MACD | -0.60 | 0.25 |
| Stochastic Oscillator | 19.89 | 68.20 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.